CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma
Background CD49d is emerging as a powerful adverse prognostic marker in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, flow cytometric testing for CD49d has not yet been widely adopted in the United States, in part due to the lack of establishment of its performance char...
Gespeichert in:
| Veröffentlicht in: | Cytometry. Part B, Clinical cytometry Clinical cytometry, 2018-01, Vol.94 (1), p.129-135 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 135 |
|---|---|
| container_issue | 1 |
| container_start_page | 129 |
| container_title | Cytometry. Part B, Clinical cytometry |
| container_volume | 94 |
| creator | Gooden, Casey E. Jones, Patricia Bates, Ruth Shallenberger, Wendy M. Surti, Urvashi Swerdlow, Steven H. Roth, Christine G. |
| description | Background
CD49d is emerging as a powerful adverse prognostic marker in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, flow cytometric testing for CD49d has not yet been widely adopted in the United States, in part due to the lack of establishment of its performance characteristics in the clinical setting, especially in comparison with the more common CLL/SLL prognostic markers CD38 and ZAP‐70.
Methods
CD49d expression levels in 124 CLL/SLL cases were assessed among peripheral blood (PB), bone marrow (BM), and lymph node (LN) specimens and correlated with available CD38 and ZAP‐70 expression and cytogenetic findings. For 10 PB/BM specimens, the stability of CD49d, CD38, and ZAP‐70 expression was assessed at |
| doi_str_mv | 10.1002/cyto.b.21384 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826687011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826687011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4024-6c893de93a34a4e22b39d7afb2098d297cd7b2403438cf6d76f521363ffa2a403</originalsourceid><addsrcrecordid>eNp9kTtPwzAUhS0E4r0xI0ssDLT1K3E8QnlKSF1gYLIcx6aBOC52oqp_g1-MQwEJBqZ7dM_n46t7ATjCaIwRIhO96vy4HBNMC7YBdnGWkRETGd_80UzsgL0YXxCiGcv5NtghnBDMcbYL3qeXTFQwzv0ywtgvTKh9gKlYH5xqtYF6roLSXTJiV-sIkwFt45dw-NiZLtQaLoJ_bv3gw86k0j7Duk0vg29Tq1m5xdwnfNCmfzWuVpPoVNP8tj61Uwdgy6ommsOvug8er68eprej-9nN3fT8fqQZImyU60LQygiqKFPMEFJSUXFlS4JEURHBdcVLwhBltNA2r3hus7SknFqriEr9fXC6zk3Tv_VpbOnqqE3TqNb4PkpckDwvOMI4oSd_0BffhzZNJ7EQFCEssixRZ2tKBx9jMFYuQu1UWEmM5HArOaxMlvLzVgk__grtS2eqH_j7OAlga2BZN2b1b5icPj3MLta5H_LKpD8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1993001955</pqid></control><display><type>article</type><title>CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Gooden, Casey E. ; Jones, Patricia ; Bates, Ruth ; Shallenberger, Wendy M. ; Surti, Urvashi ; Swerdlow, Steven H. ; Roth, Christine G.</creator><creatorcontrib>Gooden, Casey E. ; Jones, Patricia ; Bates, Ruth ; Shallenberger, Wendy M. ; Surti, Urvashi ; Swerdlow, Steven H. ; Roth, Christine G.</creatorcontrib><description>Background
CD49d is emerging as a powerful adverse prognostic marker in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, flow cytometric testing for CD49d has not yet been widely adopted in the United States, in part due to the lack of establishment of its performance characteristics in the clinical setting, especially in comparison with the more common CLL/SLL prognostic markers CD38 and ZAP‐70.
Methods
CD49d expression levels in 124 CLL/SLL cases were assessed among peripheral blood (PB), bone marrow (BM), and lymph node (LN) specimens and correlated with available CD38 and ZAP‐70 expression and cytogenetic findings. For 10 PB/BM specimens, the stability of CD49d, CD38, and ZAP‐70 expression was assessed at <24 hours, 48 hours, 72 hours, and 96 hours.
Results
39% (28 of 71) PB, 56% (18 of 32) BM, and 71% (15 of 21) LN involved by CLL/SLL were CD49d+, using a ≥30% threshold. The mean for the CD49d+ cases was 2.8 standard deviations (SD) above the cutoff for positivity, compared with 1.7 SD for CD38 and 1.1 SD for ZAP‐70. CD49d demonstrated the lowest mean SD (0.91) and coefficient of variation (CV) (8.0%) compared with CD38 (SD = 2.1, CV = 10.4%) and ZAP‐70 (SD = 9.8, CV = 40.5%) in stability studies over a 96‐hours time period. CD49d+ CLL/SLL correlated with trisomy 12 (P = 0.025) and lack of isolated deletion (13q) (P = 0.005). CD38+ CLL/SLL correlated with deletion (11q) (P = 0.025). ZAP‐70 did not correlate with any underlying cytogenetic abnormality.
Conclusions
CD49d is a robust adverse prognostic marker in CLL/SLL with superior performance characteristics. © 2016 International Clinical Cytometry Society</description><identifier>ISSN: 1552-4949</identifier><identifier>EISSN: 1552-4957</identifier><identifier>DOI: 10.1002/cyto.b.21384</identifier><identifier>PMID: 27221715</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Bone marrow ; CD38 ; CD38 antigen ; CD49d ; CD49d antigen ; Chronic lymphocytic leukemia ; CLL/SLL ; Coefficient of variation ; Cytometry ; Flow cytometry ; Leukemia ; Lymph nodes ; Lymphatic leukemia ; Lymphocyte receptors ; Lymphoma ; Peripheral blood ; Stability analysis ; Trisomy ; ZAP-70 protein ; ZAP‐70</subject><ispartof>Cytometry. Part B, Clinical cytometry, 2018-01, Vol.94 (1), p.129-135</ispartof><rights>2016 International Clinical Cytometry Society</rights><rights>2016 International Clinical Cytometry Society.</rights><rights>2018 International Clinical Cytometry Society</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4024-6c893de93a34a4e22b39d7afb2098d297cd7b2403438cf6d76f521363ffa2a403</citedby><cites>FETCH-LOGICAL-c4024-6c893de93a34a4e22b39d7afb2098d297cd7b2403438cf6d76f521363ffa2a403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcyto.b.21384$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcyto.b.21384$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27221715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gooden, Casey E.</creatorcontrib><creatorcontrib>Jones, Patricia</creatorcontrib><creatorcontrib>Bates, Ruth</creatorcontrib><creatorcontrib>Shallenberger, Wendy M.</creatorcontrib><creatorcontrib>Surti, Urvashi</creatorcontrib><creatorcontrib>Swerdlow, Steven H.</creatorcontrib><creatorcontrib>Roth, Christine G.</creatorcontrib><title>CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma</title><title>Cytometry. Part B, Clinical cytometry</title><addtitle>Cytometry B Clin Cytom</addtitle><description>Background
CD49d is emerging as a powerful adverse prognostic marker in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, flow cytometric testing for CD49d has not yet been widely adopted in the United States, in part due to the lack of establishment of its performance characteristics in the clinical setting, especially in comparison with the more common CLL/SLL prognostic markers CD38 and ZAP‐70.
Methods
CD49d expression levels in 124 CLL/SLL cases were assessed among peripheral blood (PB), bone marrow (BM), and lymph node (LN) specimens and correlated with available CD38 and ZAP‐70 expression and cytogenetic findings. For 10 PB/BM specimens, the stability of CD49d, CD38, and ZAP‐70 expression was assessed at <24 hours, 48 hours, 72 hours, and 96 hours.
Results
39% (28 of 71) PB, 56% (18 of 32) BM, and 71% (15 of 21) LN involved by CLL/SLL were CD49d+, using a ≥30% threshold. The mean for the CD49d+ cases was 2.8 standard deviations (SD) above the cutoff for positivity, compared with 1.7 SD for CD38 and 1.1 SD for ZAP‐70. CD49d demonstrated the lowest mean SD (0.91) and coefficient of variation (CV) (8.0%) compared with CD38 (SD = 2.1, CV = 10.4%) and ZAP‐70 (SD = 9.8, CV = 40.5%) in stability studies over a 96‐hours time period. CD49d+ CLL/SLL correlated with trisomy 12 (P = 0.025) and lack of isolated deletion (13q) (P = 0.005). CD38+ CLL/SLL correlated with deletion (11q) (P = 0.025). ZAP‐70 did not correlate with any underlying cytogenetic abnormality.
Conclusions
CD49d is a robust adverse prognostic marker in CLL/SLL with superior performance characteristics. © 2016 International Clinical Cytometry Society</description><subject>Bone marrow</subject><subject>CD38</subject><subject>CD38 antigen</subject><subject>CD49d</subject><subject>CD49d antigen</subject><subject>Chronic lymphocytic leukemia</subject><subject>CLL/SLL</subject><subject>Coefficient of variation</subject><subject>Cytometry</subject><subject>Flow cytometry</subject><subject>Leukemia</subject><subject>Lymph nodes</subject><subject>Lymphatic leukemia</subject><subject>Lymphocyte receptors</subject><subject>Lymphoma</subject><subject>Peripheral blood</subject><subject>Stability analysis</subject><subject>Trisomy</subject><subject>ZAP-70 protein</subject><subject>ZAP‐70</subject><issn>1552-4949</issn><issn>1552-4957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kTtPwzAUhS0E4r0xI0ssDLT1K3E8QnlKSF1gYLIcx6aBOC52oqp_g1-MQwEJBqZ7dM_n46t7ATjCaIwRIhO96vy4HBNMC7YBdnGWkRETGd_80UzsgL0YXxCiGcv5NtghnBDMcbYL3qeXTFQwzv0ywtgvTKh9gKlYH5xqtYF6roLSXTJiV-sIkwFt45dw-NiZLtQaLoJ_bv3gw86k0j7Duk0vg29Tq1m5xdwnfNCmfzWuVpPoVNP8tj61Uwdgy6ommsOvug8er68eprej-9nN3fT8fqQZImyU60LQygiqKFPMEFJSUXFlS4JEURHBdcVLwhBltNA2r3hus7SknFqriEr9fXC6zk3Tv_VpbOnqqE3TqNb4PkpckDwvOMI4oSd_0BffhzZNJ7EQFCEssixRZ2tKBx9jMFYuQu1UWEmM5HArOaxMlvLzVgk__grtS2eqH_j7OAlga2BZN2b1b5icPj3MLta5H_LKpD8</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Gooden, Casey E.</creator><creator>Jones, Patricia</creator><creator>Bates, Ruth</creator><creator>Shallenberger, Wendy M.</creator><creator>Surti, Urvashi</creator><creator>Swerdlow, Steven H.</creator><creator>Roth, Christine G.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201801</creationdate><title>CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma</title><author>Gooden, Casey E. ; Jones, Patricia ; Bates, Ruth ; Shallenberger, Wendy M. ; Surti, Urvashi ; Swerdlow, Steven H. ; Roth, Christine G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4024-6c893de93a34a4e22b39d7afb2098d297cd7b2403438cf6d76f521363ffa2a403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Bone marrow</topic><topic>CD38</topic><topic>CD38 antigen</topic><topic>CD49d</topic><topic>CD49d antigen</topic><topic>Chronic lymphocytic leukemia</topic><topic>CLL/SLL</topic><topic>Coefficient of variation</topic><topic>Cytometry</topic><topic>Flow cytometry</topic><topic>Leukemia</topic><topic>Lymph nodes</topic><topic>Lymphatic leukemia</topic><topic>Lymphocyte receptors</topic><topic>Lymphoma</topic><topic>Peripheral blood</topic><topic>Stability analysis</topic><topic>Trisomy</topic><topic>ZAP-70 protein</topic><topic>ZAP‐70</topic><toplevel>online_resources</toplevel><creatorcontrib>Gooden, Casey E.</creatorcontrib><creatorcontrib>Jones, Patricia</creatorcontrib><creatorcontrib>Bates, Ruth</creatorcontrib><creatorcontrib>Shallenberger, Wendy M.</creatorcontrib><creatorcontrib>Surti, Urvashi</creatorcontrib><creatorcontrib>Swerdlow, Steven H.</creatorcontrib><creatorcontrib>Roth, Christine G.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cytometry. Part B, Clinical cytometry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gooden, Casey E.</au><au>Jones, Patricia</au><au>Bates, Ruth</au><au>Shallenberger, Wendy M.</au><au>Surti, Urvashi</au><au>Swerdlow, Steven H.</au><au>Roth, Christine G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma</atitle><jtitle>Cytometry. Part B, Clinical cytometry</jtitle><addtitle>Cytometry B Clin Cytom</addtitle><date>2018-01</date><risdate>2018</risdate><volume>94</volume><issue>1</issue><spage>129</spage><epage>135</epage><pages>129-135</pages><issn>1552-4949</issn><eissn>1552-4957</eissn><abstract>Background
CD49d is emerging as a powerful adverse prognostic marker in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, flow cytometric testing for CD49d has not yet been widely adopted in the United States, in part due to the lack of establishment of its performance characteristics in the clinical setting, especially in comparison with the more common CLL/SLL prognostic markers CD38 and ZAP‐70.
Methods
CD49d expression levels in 124 CLL/SLL cases were assessed among peripheral blood (PB), bone marrow (BM), and lymph node (LN) specimens and correlated with available CD38 and ZAP‐70 expression and cytogenetic findings. For 10 PB/BM specimens, the stability of CD49d, CD38, and ZAP‐70 expression was assessed at <24 hours, 48 hours, 72 hours, and 96 hours.
Results
39% (28 of 71) PB, 56% (18 of 32) BM, and 71% (15 of 21) LN involved by CLL/SLL were CD49d+, using a ≥30% threshold. The mean for the CD49d+ cases was 2.8 standard deviations (SD) above the cutoff for positivity, compared with 1.7 SD for CD38 and 1.1 SD for ZAP‐70. CD49d demonstrated the lowest mean SD (0.91) and coefficient of variation (CV) (8.0%) compared with CD38 (SD = 2.1, CV = 10.4%) and ZAP‐70 (SD = 9.8, CV = 40.5%) in stability studies over a 96‐hours time period. CD49d+ CLL/SLL correlated with trisomy 12 (P = 0.025) and lack of isolated deletion (13q) (P = 0.005). CD38+ CLL/SLL correlated with deletion (11q) (P = 0.025). ZAP‐70 did not correlate with any underlying cytogenetic abnormality.
Conclusions
CD49d is a robust adverse prognostic marker in CLL/SLL with superior performance characteristics. © 2016 International Clinical Cytometry Society</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27221715</pmid><doi>10.1002/cyto.b.21384</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1552-4949 |
| ispartof | Cytometry. Part B, Clinical cytometry, 2018-01, Vol.94 (1), p.129-135 |
| issn | 1552-4949 1552-4957 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826687011 |
| source | Wiley Free Content; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Bone marrow CD38 CD38 antigen CD49d CD49d antigen Chronic lymphocytic leukemia CLL/SLL Coefficient of variation Cytometry Flow cytometry Leukemia Lymph nodes Lymphatic leukemia Lymphocyte receptors Lymphoma Peripheral blood Stability analysis Trisomy ZAP-70 protein ZAP‐70 |
| title | CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T05%3A57%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD49d%20shows%20superior%20performance%20characteristics%20for%20flow%20cytometric%20prognostic%20testing%20in%20chronic%20lymphocytic%20leukemia/small%20lymphocytic%20lymphoma&rft.jtitle=Cytometry.%20Part%20B,%20Clinical%20cytometry&rft.au=Gooden,%20Casey%20E.&rft.date=2018-01&rft.volume=94&rft.issue=1&rft.spage=129&rft.epage=135&rft.pages=129-135&rft.issn=1552-4949&rft.eissn=1552-4957&rft_id=info:doi/10.1002/cyto.b.21384&rft_dat=%3Cproquest_cross%3E1826687011%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1993001955&rft_id=info:pmid/27221715&rfr_iscdi=true |